Zhengyun Zou
Overview
Explore the profile of Zhengyun Zou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang R, Wang J, Zheng K, Zhao M, Zou Z
Front Public Health
. 2025 Feb;
13:1496082.
PMID: 39963482
Objectives: This study aimed to investigate the impact of socioeconomic status on survival in Chinese patients with acral melanoma. Methods: We collected clinical and socioeconomic information of 298 primary acral...
2.
Kang X, Han Y, Wu M, Li Y, Qian P, Xu C, et al.
Mol Ther
. 2025 Jan;
33(3):1300.
PMID: 39855188
No abstract available.
3.
Kang X, Han Y, Wu M, Li Y, Qian P, Xu C, et al.
Mol Ther
. 2024 Dec;
33(2):670-687.
PMID: 39690741
Tumor necrosis factor (TNF) has been recognized as an immune activation factor in tumor immunotherapy. Our study demonstrated that TNF blockade markedly enhanced the antitumor efficacy of oncolytic adenovirus (AdV)...
4.
Zhao L, Ren Y, Zhang G, Zheng K, Wang J, Sha H, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38908858
Background: Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors. We aimed to assess the efficacy and safety...
5.
Shi T, Sun M, Tuerhong S, Li M, Wang J, Wang Y, et al.
Biomaterials
. 2024 May;
309:122607.
PMID: 38759487
The use of CAR-T cells in treating solid tumors frequently faces significant challenges, mainly due to the heterogeneity of tumor antigens. This study assessed the efficacy of an acidity-targeting transition-aided...
6.
Qin L, Zhang G, Wu Y, Yang Y, Zou Z
Cancer Immunol Immunother
. 2024 Apr;
73(6):103.
PMID: 38630135
As one of the scheduled immunization vaccines worldwide, virtually all individuals have been vaccinated with BCG vaccine. In order to verify the hypothesis that delivering BCG high-affinity peptides to tumor...
7.
Huang R, Zhao M, Zhang G, Yang Y, Wang J, Zheng K, et al.
Cancer Med
. 2024 Mar;
13(7):e7137.
PMID: 38545846
Introduction: Acral melanoma (AM) is the most common subtype of malignant melanoma in China, with a very poor prognosis. Despite the frequent reporting of trauma events in AM cases, the...
8.
Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, et al.
Eur J Cancer
. 2024 Mar;
202:114008.
PMID: 38479118
Background: NRAS-mutant melanoma is an aggressive subtype with poor prognosis; however, there is no approved targeted therapy to date worldwide. Methods: We conducted a multicenter, single-arm, phase II, pivotal registrational...
9.
Cui C, Chen Y, Luo Z, Zou Z, Jiang Y, Pan H, et al.
BMC Cancer
. 2023 Feb;
23(1):121.
PMID: 36747118
Background: Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands...
10.
Huang R, Shen G, Ren Y, Zheng K, Wang J, Shi Y, et al.
J Transl Med
. 2023 Feb;
21(1):78.
PMID: 36739402
Background: Acral melanoma (AM) is the most common subtype in Chinese melanoma patients with a very poor prognosis. However, our understanding of the disease pathogenesis and molecular landscape is limited...